Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Accounts Payables (2016 - 2026)

Wave Life Sciences (WVE) has disclosed Accounts Payables for 12 consecutive years, with $19.1 million as the latest value for Q1 2026.

  • For Q1 2026, Accounts Payables rose 32.78% year-over-year to $19.1 million; the TTM value through Mar 2026 reached $19.1 million, up 32.78%, while the annual FY2025 figure was $15.7 million, 3.46% down from the prior year.
  • Accounts Payables hit $19.1 million in Q1 2026 for Wave Life Sciences, up from $15.7 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $19.1 million in Q1 2026 and bottomed at $9.9 million in Q1 2022.
  • Average Accounts Payables over 5 years is $14.2 million, with a median of $14.4 million recorded in 2025.
  • On a YoY basis, Accounts Payables climbed as much as 132.32% in 2022 and fell as far as 26.57% in 2022.
  • Wave Life Sciences' Accounts Payables stood at $16.9 million in 2022, then dropped by 24.1% to $12.8 million in 2023, then grew by 26.66% to $16.3 million in 2024, then dropped by 3.46% to $15.7 million in 2025, then rose by 21.43% to $19.1 million in 2026.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $19.1 million, $15.7 million, and $14.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.